Seagen
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Nurix and Seagen Join Forces to Pioneer Cancer Therapies by Combining Protein Degradation and ADC Technologies
Seagen has just sealed a strategic partnership with Nurix Therapeutics, headquartered in San Francisco. This collaboration is poised to unlock ...
Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
Pfizer reveals executive leadership to advance its oncology R&D strategy
Source – Pfizer Pfizer has unveiled significant executive leadership changes aimed at advancing its commitment to research and development of ...
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...
98% ORR in Early-Stage Classical Hodgkin Lymphoma with Brentuximab Vedotin + Nivolumab/Chemo
Source – Seagen Frontline treatment with the combination of brentuximab vedotin (Adcetris), nivolumab (Opdivo), doxorubicin, and dacarbazine led to an ...
Pfizer updates papers for its $43 billion acquisition of Seagen as the FTC keeps a watch on biopharma M&A deals
Source: Pfizer A month later, Pfizer withdrew its notice for its proposed $43 billion acquisition of cancer medication expert Seagen ...
